COMMUNIQUÉS West-GlobeNewswire

GW Pharmaceuticals plc Announces the Sale of Priority Review Voucher for $105M
18/03/2019
CARLSBAD, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, [...]
Kiniksa Presents Rilonacept Interim Phase 2 Clinical Data Poster at the American College of Cardiology’s 68th Annual Scientific Session
18/03/2019
- Interim clinical data show reductions in both inflammation and reported pain throughout the treatment period - Enrollment is ongoing in RHAPSODY, Kiniksa’s pivotal Phase 3 trial of rilonacept in recurrent pericarditis [...]
Motif Bio Announces Appointment of Bruce Williams as Interim Chairman and Resignation of Richard Morgan from the Board
18/03/2019
NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Richard C. E. Morgan has [...]
CMR Surgical strengthens Board of Directors
18/03/2019
CMR Surgical Limited ("CMR Surgical" or the "Company") CMR Surgical strengthens Board of Directors Cambridge, UK, 18 March 2019 : CMR Surgical Ltd, the British company developing a next-generation surgical robot, today [...]
Nicox présente des données non cliniques sur le NCX 4251, une nouvelle thérapie pour la blépharite, dans un poster à l'AGS 2019 Annual Meeting
18/03/2019
Communiqué de presse Nicox présente des données non cliniques sur le NCX 4251, une nouvelle thérapie pour la blépharite, dans un poster à l'AGS 2019 Annual Meeting ............................................... NCX [...]
Nicox Poster Presentation at AGS 2019 Annual Meeting Discloses Preclinical Data for NCX 4251, a Novel Blepharitis Therapy
18/03/2019
Press Release Nicox Poster Presentation at AGS 2019 Annual Meeting Discloses Preclinical Data for NCX 4251, a Novel Blepharitis Therapy ............................................... NCX 4251 is a novel therapy in [...]
Alcon Announces Acquisition of PowerVision, Inc.
18/03/2019
Acquisition demonstrates Alcon's commitment to driving growth and innovation in advanced technology intraocular lenses (AT-IOLS) to meet the needs of cataract surgery patients who desire spectacle independence US-based [...]
MDxHealth (R): MDxHealth Announces Positive Data from Pan-European Clinical Validation Study of SelectMDx
18/03/2019
NEWS RELEASE SelectMDx demonstrates accurate identification of both low-risk and aggressive prostate cancer across all patient groups IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CET, March 18, 2019 - MDxHealth SA (Euronext [...]
MDxHealth (R) : MDxHealth annonce des données positives provenant d'une étude paneuropéenne Étude de validation clinique de SelectMDx
18/03/2019
COMMUNIQUÉ DE PRESSE SelectMDx permet une identification précise du cancer de la prostate à faible risque et du cancer de la prostate agressif dans tous les groupes de patients. IRVINE, CA, et HERSTAL, BELGIQUE - 07h00 [...]
Bone Therapeutics to present data at Herbert Fleisch / IFMRS Workshop
18/03/2019
Press release Gosselies, Belgium, 18 March 2019, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, [...]
DEFINE PCI study finds treatable cause for significant rates of residual ischemia in coronary stent patients
17/03/2019
March 17, 2019 Nearly one in four patients in the study treated with standard of care percutaneous coronary intervention (PCI) had residual ischemia after coronary stent implantation intended to relieve severe blockages [...]
Full Results from PhaseBio Phase 1 Clinical Trial of PB2452 Published in the New England Journal of Medicine and Presented at the American College of Cardiology’s 68th Annual Scientific Session
17/03/2019
PB2452 achieved immediate and sustained reversal of ticagrelor antiplatelet effects Results support continued development of PB2452 as ticagrelor reversal agent MALVERN, Penn. and SAN DIEGO, March 17, 2019 (GLOBE [...]
New Clinical Trial Shows Medtronic TYRX(TM) Envelope Signficantly Reduces Major Infections in Cardiac Implantable Device Patients
17/03/2019
Late-Breaking Trial Results Presented at ACC Scientific Sessions and Published in The New England Journal of Medicine WRAP-IT is the Largest Randomized Global Trial Ever Conducted with Cardiac Implanted Electronic [...]
High Risk of Atherosclerotic Cardiovascular Events Projected in People with Elevated Triglycerides Without Established Atherosclerotic Cardiovascular Disease
16/03/2019
BEDMINSTER, N.J. and DUBLIN, Ireland, March 16, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, announced today the presentation of [...]
Medtronic Evolut Low Risk Trial Meets Primary Endpont
16/03/2019
Less Invasive Evolut(TM) Transcatheter Aortic Valve Replacement (TAVR) System Successful in Clinical Trial When Compared to Open Heart Surgery in Healthier Aortic Stenosis Patients DUBLIN and NEW ORLEANS - March 16, [...]
The Woman’s Hospital of Texas Welcomes Sextuplets!!
16/03/2019
HOUSTON, March 15, 2019 (GLOBE NEWSWIRE) -- The Woman’s Hospital of Texas, an HCA Houston Healthcare Affiliate, which delivers more babies than any other Texas hospital, early this morning welcomed sextuplets, the odds [...]
Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
16/03/2019
France, March 16, 2019 (GLOBE NEWSWIRE) -- Praluent ® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease Approval is based on [...]
Allergy Standards Ltd deepens footprint in the ‘Bay Area’ as Irish Minister for Health visits
15/03/2019
SAN FRANCISCO, March 15, 2019 (GLOBE NEWSWIRE) -- Allergy Standards Limited (ASL) has been expanding its activities on the West Coast and a visit to San Francisco, Berkeley, and Los Angeles by its CEO Dr. John McKeon [...]
Helix BioPharma Corp. Closes Private Placement, Extends Period to Exercise Warrants and Provides Corporate Update
15/03/2019
RICHMOND HILL, Ontario, March 15, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and [...]

Pages